Business Context and Reporting Period
This Form 8-K was filed by Halozyme Therapeutics, Inc. on December 15, 2006. The filing reports the entry into a material definitive agreement involving an amendment to an existing commercial supply contract.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a contractual amendment rather than financial performance data.
Material Changes
On December 15, 2006, the Company entered into Amendment No. 1 to its Commercial Supply Agreement with Avid Bioservices, Inc. (Avid), originally dated February 16, 2005. Key changes include:
- Manufacturing Forecasts: Halozyme will begin providing manufacturing forecasts to Avid starting January 1, 2007.
- Supply Rights: Avid is granted the right to manufacture and supply a certain percentage of the Company's recombinant human enzyme used in the Cumulase and Hylenex products.
- Term Extension: The initial term of the Agreement was extended to February 2010.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on financial outlook, or specific risk factors beyond the standard qualification that the summary is not complete and is subject to the full text of the Amendment (Exhibit 99.1). Portions of the exhibit were omitted due to a request for confidential treatment.
Investor Verification Checklist
- Verify the specific percentage of recombinant human enzyme supply rights granted to Avid, as the filing states "a certain percentage" without specifying the figure.
- Review Exhibit 99.1 (Amendment No. 1) for the complete terms, noting that confidential portions were omitted from the public filing.
- Confirm the operational impact of the January 1, 2007 forecast requirement on the Company's supply chain planning.
- Assess the strategic implications of extending the supply agreement term to 2010 for the Cumulase and Hylenex product lines.